This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2008 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 27, 2007
Last updated: October 28, 2013
Last verified: November 2008

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors.

PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire works in assessing the quality of life of patients with gastrointestinal-related neuroendocrine tumors.

Condition Intervention Phase
Gastrointestinal Carcinoid Tumor Islet Cell Tumor Lung Cancer Metastatic Cancer Neoplastic Syndrome Other: questionnaire administration Procedure: quality-of-life assessment Phase 4

Study Type: Observational
Official Title: Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)

Secondary Outcome Measures:
  • Response to change after various treatments

Estimated Enrollment: 408
Study Start Date: October 2006
Detailed Description:



  • Test the scale structure, reliability, and validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21) in patients with gastrointestinal-related neuroendocrine tumors.


  • Determine the quality of life of patients using QLQ-C30 and the QLQ-G.I.NET21 before and after treatment.

OUTLINE: This is a multicenter study. Patients are stratified according to treatment (somatostatin analogue therapy or interferon therapy vs radionuclide therapy or chemotherapy vs ablative therapies [embolization or radiofrequency ablation] or liver resection).

Patients complete the EORTC C30 questionnaire, QLQ-G.I.NET21 module, and are evaluated for Karnofsky performance status at pretreatment, at 3 and 6 months after treatment, and then 2 weeks later. Patients also complete a clinical data and sociodemographic data form and debriefing questionnaire at pretreatment; a follow-up form at 3 months and 6 months after treatment; and a test-retest form 2 weeks later.

PROJECTED ACCRUAL: A total of 408 patients will be accrued for this study.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed neuroendocrine tumor OR characteristic radiological findings of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of the following criteria:

    • Primary disease in gut with liver metastases (with or without hormone secretion)
    • Primary disease in lung with liver or abdominal metastases (with or without hormone secretion)
    • Primary disease in pancreas with or without metastases (with or without hormone secretion)


  • Any Karnofsky performance status allowed
  • Life expectancy ≥ 3 months
  • Able to understand the questionnaire language
  • Mentally fit to complete questionnaire
  • No psychological, familial, sociological, or geographical condition that would limit study compliance
  • No other concurrent malignancies except basal cell carcinoma of the skin


  • More than 2 months since prior somatostatin analogue or interferon therapy (somatostatin therapy stratum)

    • Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable over the past month
  • More than 6 months since prior radionuclide therapy or systemic chemotherapy (radionuclide or systemic chemotherapy stratum)
  • More than 6 months since prior ablative therapies (ablative therapy stratum)
  • No concurrent participation in other quality of life studies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00454376

Aarhus Universitetshospital - Aarhus Sygehus
Aarhus, Denmark, DK 8000
Charite - Campus Charite Mitte
Berlin, Germany, D-10117
Klinikum der Universitaet Regensburg
Regensburg, Germany, D-93053
University Athens Alexandras Hospital
Athens, Greece, 611
Hadassah University Hospital
Jerusalem, Israel, 91120
Clinical and Experimental Medicine at the University of Verona
Verona, Italy, 37129
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital
Amsterdam, Netherlands, 1066 CX
Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology - Warsaw
Warsaw, Poland, 02-781
Hospital Universitario San Carlos
Madrid, Spain, 28040
Uppsala University Hospital
Uppsala, Sweden, SE-75185
United Kingdom
Basingstoke and North Hampshire NHS Foundation Trust
Basingstoke, England, United Kingdom, RG24 9NA
Aintree University Hospital
Liverpool, England, United Kingdom, L9 7AL
UCL Cancer Institute
London, England, United Kingdom, NW1 2QG
King's College Hospital
London, England, United Kingdom, SE5 9RS
Southampton General Hospital
Southampton, England, United Kingdom, SO16 6YD
Royal Victoria Hospital
Belfast, Northern Ireland, United Kingdom, BT12 6BA
Sponsors and Collaborators
National Cancer Institute (NCI)
Study Chair: John K. Ramage, MD Basingstoke and North Hampshire NHS Foundation Trust
  More Information Identifier: NCT00454376     History of Changes
Other Study ID Numbers: CDR0000537344
Study First Received: March 27, 2007
Last Updated: October 28, 2013

Keywords provided by National Cancer Institute (NCI):
metastatic gastrointestinal carcinoid tumor
recurrent gastrointestinal carcinoid tumor
pulmonary carcinoid tumor
WDHA syndrome
pancreatic polypeptide tumor
liver metastases

Additional relevant MeSH terms:
Neuroendocrine Tumors
Carcinoid Tumor
Neoplasm Metastasis
Malignant Carcinoid Syndrome
Gastrointestinal Neoplasms
Adenoma, Islet Cell
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Glandular and Epithelial
Neoplastic Processes
Pathologic Processes
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Pancreatic Neoplasms
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases processed this record on September 21, 2017